Immunic, Inc. IMUX Income Statement

Immunic, inc. (IMUX)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Operating expenses:
Research and development
25,591	22,512	12,357	6,665	2,793	9,595	23,914	32,193	39,870	39,341	38,013	35,793	32,817	30,046	28,013	30,190	34,877	39,773	43,835	44,433	42,013	39,479	36,242	32,161	27,574	21,787	0	0	0
General and administrative
15,793	14,520	9,519	7,839	-626	2,402	9,833	12,388	14,590	13,314	11,687	11,507	11,480	11,220	11,318	11,237	12,082	12,347	12,413	12,290	11,270	10,863	10,330	10,766	10,778	9,615	0	0	0
Severance costs
-	-	-	-	-	-	-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of Long-Lived Assets Held-for-use
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
41,384	37,032	21,876	14,504	2,167	11,997	33,747	44,581	54,460	52,655	49,700	47,300	44,297	41,266	39,331	41,427	46,959	52,120	56,248	56,723	53,283	50,342	46,572	42,927	38,352	31,402	0	0	0
Loss from operations
-41,384	-37,032	-21,876	-14,504	-2,167	-11,997	-33,747	-44,581	-54,460	-52,655	-49,700	-47,300	-44,297	-41,266	-39,331	-41,427	-46,959	-52,120	-56,248	-56,723	-53,283	-50,342	-46,572	-42,927	-38,352	-31,402	0	0	0
Other income (expense):
Interest income
131	107	505	447	0	-	367	554	723	650	523	415	321	284	237	171	108	58	43	35	27	19	12	8	5	5	0	0	0
Other income, net
2,146	1,992	2,026	1,130	871	456	-63	-100	-127	-73	-47	-36	-6	13	0	40	-3	39	87	72	107	56	-5	-16	0	-	0	0	-
Revaluation of future purchase rights liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,600	2,614	4,806	4,256	-1,306	0	0	0
Total other income
2,277	2,099	1,947	993	700	455	304	454	596	577	476	379	315	297	237	211	105	97	130	107	1,606	2,675	2,620	4,796	4,244	-1,316	0	0	0
Net loss
-39,107	-34,933	-19,929	-13,511	-1,467	-11,542	-33,443	-44,127	-53,864	-52,078	-49,224	-46,921	-43,982	-40,969	-39,094	-41,216	-46,854	-52,023	-56,118	-56,616	-51,677	-47,667	-41,856	-36,035	-33,135	-32,718	0	0	0
Net loss before cumulative effect of change in accounting principle
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Amortization of deemed dividend
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,744	4,787	4,797	83	64	0	0	0
Accretion to redemption value of redeemable convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,410	6,581	8,628	8,381	6,303	0	0	0
Net loss attributable to common stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-56,821	-51,901	0	0	-	0	-	-
Net loss per share, basic and diluted (in USD per share)
-0.79	2.91	-0.82	-1.52	-5.09	-8.02	-2.12	-3.15	-0.34	-0.33	-0.30	-0.29	-0.39	-0.38	-0.32	-0.30	-0.31	-0.31	-0.51	-0.63	-0.62	22.45	-0.59	-0.91	-24.49	-22.11	-16.31	-14.33	-22.11
Weighted Average Number of Shares Outstanding, Basic
-	-	-	-	-	-	-	-	42,368	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted-average common shares outstanding, basic and diluted (in shares)
10,749	10,350	10,022	9,669	846	-	846	846	-	42,376	42,207	42,207	32,645	32,094	31,645	31,247	30,563	28,617	24,025	23,996	23,972	24,006	21,759	17,888	564	560	553	507	467